A Randomized, Double-Blind, Placebo Controlled, Safety and Tolerability Study of Intracerebroventricular Administration of sNN0031 to Patients With Idiopathic Parkinson's Disease (PD) of Moderate Severity, Using an Implanted Catheter and a SynchroMed II Pump.
Latest Information Update: 10 Nov 2021
Price :
$35 *
At a glance
- Drugs SNN 0031 (Primary)
- Indications Parkinson's disease
- Focus Adverse reactions
- Sponsors Newron Pharmaceuticals
- 19 Jun 2013 Results were presented at the 17th International Congress of Parkinson's disease and Movement Disorders, according to a Newron Pharmaceuticals media release.
- 14 Jun 2013 Results will be presented at the 17th International Congress of Parkinson's disease and Movement Disorders, according to a Newron Pharmaceuticals media release.
- 24 Mar 2012 Actual initiation date changed from 1 Mar 2009 to 28 Jan 2009 as reported by European Clinical Trials Database.